^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
APIS Assay Techno

i
Other names: APIS Assay Techno | APIS Assay Technologies
Related tests:
Evidence

News

3ms
APIS releases first publication on Breast Cancer Subtyping Kit (APIS Press Release)
"The article is titled ‘Comprehensive and Accurate Molecular Profiling of Breast Cancer through mRNA Expression of ESR1, PGR, ERBB2, MKI67, and a Novel Proliferation Signature‘ published in MDPI."
Clinical data
|
APIS Breast Cancer Subtyping Kit
6ms
Press release Biocartis group NV: Biocartis honors breast cancer awareness month with launch of breast cancer portfolio (Biocartis Press Release)
"Biocartis Group NV...announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (APIS), the APIS Breast Cancer Subtyping Kit and the APIS ESR1 Mutations Kit."
Licensing / partnership • Launch
|
APIS Breast Cancer Subtyping Kit • APIS ESR1 Mutations Kit • Idylla™ PIK3CA-AKT1 Mutation Assay
6ms
Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit (GlobeNewswire)
"Biocartis Group NV...and APIS Assay Technologies Ltd...today announced the expansion of their partnership to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis’ worldwide commercial network....'Together with the Idylla™ PIK3CA-AKT1 Mutation Assay and the APIS Breast Cancer Subtyping Kit we will be able to provide a comprehensive menu of products in the breast cancer domain to our customers.'"
Licensing / partnership
|
APIS ESR1 Mutations Kit
1year
Press release Biocartis Group NV: Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla platform (GlobeNewswire)
"Biocartis Group NV...and APIS Assay Technologies Ltd...announce that they have entered into a new partnership agreement which targets the development of APIS’ Breast Cancer Subtyping assay on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla™....Under the terms of the partnership agreement, APIS will lead the development of the Breast Cancer Subtyping test on Idylla™, while Biocartis will lead the commercialisation through its growing Idylla™ network."
Licensing / partnership
|
APIS Breast Cancer Subtyping Kit